Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Cryofocus Medtech (Shanghai) Co. Ltd. Class H ( (HK:6922) ).
Cryofocus Medtech (Shanghai) Co., Ltd. has announced its 2024 Annual General Meeting, scheduled for June 20, 2025, in Shanghai. The meeting will address several key resolutions, including the approval of the 2024 work reports, profit distribution plan, and financial statements. Additionally, the company seeks to re-appoint Ernst & Young as auditors and grant a general mandate to issue additional shares, potentially impacting the company’s capital structure and market operations.
More about Cryofocus Medtech (Shanghai) Co. Ltd. Class H
Cryofocus Medtech (Shanghai) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the medical technology industry. The company focuses on developing and providing advanced medical solutions, with a market presence that includes the trading of H Shares on the Hong Kong Stock Exchange.
YTD Price Performance: -44.85%
Average Trading Volume: 70,244
Technical Sentiment Signal: Buy
See more insights into 6922 stock on TipRanks’ Stock Analysis page.